Danger of Medtronic's Sprint Fidelis ICD lead is increasing, scientists warn
This article was originally published in Clinica
Executive Summary
The Sprint Fidelis heart lead, which was withdrawn from the market by its manufacturer, Medtronic, in October 2007, may be even more dangerous than previously thought.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.